| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| NEUTRAL | NEUTRAL | BUY | BUY | NEUTRAL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.90▲ | 1.93▼ | 1.94▼ | 1.85▲ | 1.72▲ |
| MA10 | 1.90▲ | 1.94▼ | 1.91▼ | 1.80▲ | 1.77▲ |
| MA20 | 1.92▼ | 1.92▼ | 1.88▲ | 1.71▲ | 1.83▲ |
| MA50 | 1.93▼ | 1.87▲ | 1.83▲ | 1.77▲ | 4.12▼ |
| MA100 | 1.89▲ | 1.82▲ | 1.75▲ | 1.85▲ | 7.71▼ |
| MA200 | 1.86▲ | 1.73▲ | 1.72▲ | 3.06▼ | 10.43▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.002▼ | -0.006▼ | 0.002▲ | 0.032▲ | 0.173▲ |
| RSI | 44.608▼ | 51.145▲ | 56.262▲ | 61.559▲ | 42.314▼ |
| STOCH | 28.333 | 32.239 | 44.748 | 69.899 | 32.725 |
| WILL %R | -33.333 | -68.421 | -66.667 | -24.528▲ | -65.381 |
| CCI | 49.534 | -80.328 | 2.899 | 156.484▲ | 14.345 |
|
Tuesday, August 05, 2025 07:20 PM
Biomea Fusion (NASDAQ:BMEA), a biotechnology firm focused on developing covalent inhibitors for metabolic diseases, released its second quarter 2025 results on August 5, 2025.
|
|
Monday, January 06, 2025 03:28 PM
Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company developing covalent small molecule drugs to treat genetically defined cancers and metabolic diseases like type 2 ...
|
|
Friday, September 27, 2024 09:50 PM
Fintel reports that on September 27, 2024, Truist Securities upgraded their outlook for Biomea Fusion (NasdaqGS:BMEA) from Hold to Buy. Analyst Price Forecast Suggests 140.57% Upside As of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 28/08/25 | 2.00 | 2.04 | 1.885 | 1.91 | 1,564,333 |
| 27/08/25 | 1.83 | 1.88 | 1.82 | 1.86 | 343,715 |
| 26/08/25 | 1.82 | 1.8499 | 1.78 | 1.83 | 291,386 |
| 25/08/25 | 1.86 | 1.95 | 1.80 | 1.81 | 794,948 |
| 22/08/25 | 1.80 | 1.85 | 1.7737 | 1.83 | 344,459 |
| 21/08/25 | 1.74 | 1.80 | 1.72 | 1.795 | 222,475 |
| 20/08/25 | 1.70 | 1.86 | 1.70 | 1.78 | 731,436 |
| 19/08/25 | 1.77 | 1.77 | 1.69 | 1.72 | 337,218 |
| 18/08/25 | 1.69 | 1.765 | 1.69 | 1.74 | 461,255 |
| 15/08/25 | 1.69 | 1.73 | 1.66 | 1.73 | 356,703 |
|
|
||||
|
|
||||
|
|